Exploring the Potential of 5-HT1 Receptor Subtypes as Therapeutic Targets for Obesity Treatment in Animal Models
Navpreet Kaur1,2, Puja Gulati1★★ Corresponding author
- 1Desh Bhagat University, Mandi Gobindgarh, Punjab, INDIA.
- 2G.H.G Khalsa College of Pharmacy, Guruar Sudhar, Punjab, INDIA.
CORRESPONDENCE
Puja Gulati
Desh Bhagat University, Mandi Gobindgarh, Punjab, INDIA.
Received: 18-10-2024; Revised: 29-12-2024; Accepted: 02-04-2025.
Volume 17, Issue 2 · pp. 353–358 · PUBLISHED · DOI: 10.5530/jyp.20251548
ABSTRACT
Background:Serotonergic system plays an important role in the energy balance evidenced by various studies. The present study was designed to investigate the involvement of 5-HT1 receptor subtype in experimental obesity. Materials and Methods:In the present study effects of chronic administration of eletriptan (2.5 and 10 mg kg-1 day-1, .p.o) specific 5-HT1receptor agonist for 8 weeks along with high fat diet to the obese rats which were pre-treated with high fat diet feeding for 8 weeks on the various parameters of obesity were analysed. Results:Treatment with eletriptan (2.5 and 10 mg kg-1 day-1, .p.o) produced significant dose dependent decrease (p<0.05) in various parameters of obesity as compared to high fat diet group. Eletriptan positively modulate the parameters of obesity. The present data demonstrated that high fat diet induced obesity was prevented by 5-HT receptor agonist eletriptan. Conclusion:Above findings give the strong evidence of involvement of 5-HT1 receptor subtype in obesity.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Kaur, N., & Gulati, P. (). Exploring the Potential of 5-HT1 Receptor Subtypes as Therapeutic Targets for Obesity Treatment in Animal Models. Journal of Young Pharmacists, 17(2), 353–358. https://doi.org/10.5530/jyp.20251548